4 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
The InflaRx Commitment Program, the success of our future clinical trials for vilobelimab's treatment of COVID-19 and other debilitating or life
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
our continued commitment to these patients." About VilobelimabVilobelimab is a first-in-class
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
– The InflaRx Commitment Program launchedIn April, 2023, the FDA issued an Emergency Use Authorization (EUA) for GOHIBIC
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
IFRX
24 Apr 24
and in the future if approved for commercial use in the U.S. or elsewhere; our ability to successfully implement The InflaRx Commitment Program, the success of our
- Prev
- 1
- Next